Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial

Abstract

Objective: Hispanics have lower rates of hypertension control compared with black and white patients. Nebivolol is a vasodilatory β1-selective blocker, with neutral metabolic effects. This phase IV trial evaluated the efficacy and safety of nebivolol in Hispanics with stage I-II hypertension.

Methods: Self-identified Hispanics with stage I-II hypertension were randomized to receive a double-blind treatment: placebo (n = 136) or nebivolol (n = 141, starting dose 5 mg/day) for 8 weeks. Nebivolol dosage could be uptitrated at 2-week intervals to 10, 20, or 40 mg/day, as needed to achieve diastolic blood pressure (DBP) control (JNC7 criteria). Efficacy outcome measures were the mean changes from baseline to the end of week 8 in trough-seated DBP (primary) and systolic blood pressure (SBP) (secondary). Safety and tolerability were also assessed.

Results: Baseline SBP/DBP (mmHg) was similar in both treatment groups (nebivolol: 156/100; placebo: 157/101). A total of 135 (96%) and 121 (89%) nebivolol- and placebo-treated participants completed the double-blind phase, respectively. Compared with the placebo, nebivolol treatment was associated with significant mean reductions in both trough-seated DBP and SBP (DBP: -11.1 mmHg vs. -7.3 mmHg, p < 0.0001; SBP: -14.1 mmHg vs. -9.3 mmHg; p = 0.001). Treatment-emergent adverse event (TEAE) rates were 17% (nebivolol) and 22% (placebo); the most frequent TEAEs were headache (4% vs. 6%, respectively), upper respiratory tract infection (2% vs. 2%), and dizziness (1% vs. 3%).

Conclusions: In Hispanics with stage I-II hypertension, 8-week nebivolol monotherapy resulted in significant reductions in blood pressure. The safety and tolerability profile of nebivolol was similar to that of placebo.

Keywords

beta-blocker blood pressure Hispanics hypertension nebivolol

References

Ambrosioni, E.A. and Borghi, C. ( 2005) Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective b-blockers in the treatment of hypertension. High Blood Pres Cardiovasc Prev 12: 27-35.

Chobanian, A.V. , Bakris, G.L. , Black, H.R. , Cushman, W.C. , Green, L.A. , Izzo Jr, J.L. et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC7 Report. JAMA 289: 2560-2572.

Chowdhury, P.P. , Balluz, L. , Okoro, C. and Strine, T. ( 2006) Leading health indicators: A comparison of Hispanics with non-Hispanic whites and non-Hispanic blacks, United States 2003. Ethn Dis 16: 534-541.

Cossrow, N. and Falkner, B. ( 2004) Race/ethnic issues in obesity and obesity-related comorbidities . J Clin Endocrinol Metab 89: 2590-2594.

Egan, B.M. , Zhao, Y. and Axon, R.N. (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 303: 2043-2050.

Flegal, K.M. , Carroll, M.D. , Ogden, C.L. and Curtin, L.R. (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241.

Fonseca, V.A. ( 2010) Effects of beta-blockers on glucose and lipid metabolism . Curr Med Res Opin 26: 615-629.

Ford, E.S. , Giles, W.H. and Dietz, W.H. ( 2002) Prevalence of the metabolic syndrome among us adults: Findings from the third national health and nutrition examination survey. JAMA 287: 356-359.

Greathouse, M. ( 2010) Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol 33: E20-E27.

10.

Lasagna, L. ( 2000) Diuretics vs. alpha-blockers for treatment of hypertension: Lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 283: 2013-2014.

11.

Lloyd-Jones, D. , Adams, R.J. , Brown, T.M. , Carnethon, M. , Dai, S. , De Simone, G. et al. (2010) Executive summary: Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121: 948-954.

12.

Manrique, C. , Whaley-Connell, A. and Sowers, J.R. ( 2009) Nebivolol in obese and non-obese hypertensive patients . J Clin Hypertens (Greenwich) 11: 309-315.

13.

Martinez-Maldonado, M. ( 1995) Hypertension in hispanics: comments on a major disease in a mix of ethnic groups. Am J Hypertens 8: 120S-123S.

14.

Mason Rp, K.R. , Malinski, C. , Jacoby, A. , Jacob, R.F. , Day, C.A. and Malinski, T. ( 2007) Nitric oxide bioavailability is lower in endothelium of healthy Mexican American donors as compared to non-Hispanic white donors: Effect of nebivolol. Circulation 116: 295.

15.

Munzel, T. and Gori, T. (2009) Nebivolol: The somewhat-different beta-adrenergic receptor blocker . J Am Coll Cardiol 54: 1491-1499.

16.

Neutel, J.M. , Smith, D.H. and Gradman, A.H. (2009) Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension . J Hum Hypertens 24: 64-73.

17.

Ostchega, Y. , Yoon, S.S. , Hughes, J. and Louis, T. ( 2008) Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. NCHS Data Brief 1-8.

18.

Park, I.U. and Taylor, A.L. ( 2007) Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: A systematic review. Ann Fam Med 5: 444-452.

19.

Pepine, C.J. , Handberg, E.M. , Cooper-Dehoff, R.M. , Marks, R.G. , Kowey, P. , Messerli, F.H. et al. (2003) A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (Invest): A randomized controlled trial. JAMA 290: 2805-2816.

20.

Poirier, L. , Cleroux, J. , Nadeau, A. and Lacourciere, Y. ( 2001) Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19: 1429-1435.

21.

Richardson, L.D. and Norris, M. (2010) Access to health and health care: How race and ethnicity matter. Mt Sinai J Med 77: 166-177.

22.

Saunders, E. , Smith, W.B. , Desalvo, K.B. and Sullivan, W.A. ( 2007) The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens ( Greenwich) 9: 866-875.

23.

Schmidt, A.C. , Graf, C. , Brixius, K. and Scholze, J. ( 2007) Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: The Yestono Study. Clin Drug Investig 27: 841-849.

24.

Stewart, S.H. and Silverstein, M.D. ( 2002) Racial and ethnic disparity in blood pressure and cholesterol measurement. J Gen Intern Med 17: 405-411.

25.

Tzemos, N. , Lim, P.O. and Macdonald, T.M. ( 2001) Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, double-blind, crossover study. Circulation 104: 511-514.

26.

US Census Bureau (2010) Population Estimates. http://www.Census.Gov (accessed 23 March 2010).

27.

Van Nueten, L. , Dupont, A.G. , Vertommen, C. , Goyvaerts, H. and Robertson, J.I. ( 1997) A dose-response trial of nebivolol in essential hypertension . J Hum Hypertens 11: 139-144.

28.

Van Nueten, L. , Taylor, F.R. and Robertson, J.I. ( 1998) Nebivolol vs. atenolol and placebo in essential hypertension: A double-blind randomised trial. J Hum Hypertens 12: 135-140.

29.

Weiss, R.J. , Weber, M.A. , Carr, A.A. and Sullivan, W.A. ( 2007) A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 9: 667-676.